India's Pharma Policy
The Department of Pharmaceuticals (DoP) is reportedly exploring the use of the ‘Essentials’ Act to regulate the prices of bulk drugs in India, according to sources familiar with the matter. This move comes as the government seeks to address potential supply chain vulnerabilities and ensure the affordability of essential medicines.
The DoP has been in discussions with industry executives to assess the current situation. The ‘Essentials’ Act, if invoked, would grant the government greater authority to control the pricing of critical pharmaceutical ingredients.
The potential implications for pharmaceutical manufacturers and investors are significant. Price controls could impact the profitability of bulk drug production, potentially affecting investment decisions in the sector. However, proponents argue that such measures are necessary to safeguard public health and ensure access to essential medicines at reasonable prices.
The move reflects a growing trend among governments globally to exert greater control over pharmaceutical supply chains and pricing, particularly in light of recent disruptions and concerns over national security. Investors will be closely monitoring the situation to assess the potential impact on their portfolio companies and future investment strategies in the Indian pharmaceutical market.
About the Author
